AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37879047
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) infusion (2 × 10^6 CAR T cells per kg) after leukapheresis and lymphodepleting chemotherapy
Trial: 37879047
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) infusion
Trial: 37879077
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin administered at 0.6 mg/m2 on day 1 and 0.3 mg/m2 on day 8 of cycle 1, then at 0.3 mg/m2 on days 1 and 8 of cycles 2-6.
Trial: 37879242
Drug: Virtual-reality exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual-reality exposure treatment (VRET)
Trial: 37879393
Drug: Returning genetic
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Returning genetic results on arsenic metabolism efficiency to inefficient metabolizers (high-risk)
Trial: 37879393
Drug: Returning genetic
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Returning genetic results on arsenic metabolism efficiency to efficient metabolizers (low-risk)
Trial: 37879536
Drug: Ivonescimab 10
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivonescimab 10 mg/kg Q3W
Trial: 37879536
Drug: Ivonescimab 20
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivonescimab 20 mg/kg Q2W
Trial: 37879536
Drug: Ivonescimab 20
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivonescimab 20 mg/kg Q3W
Trial: 37879536
Drug: Ivonescimab 30
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivonescimab 30 mg/kg Q3W
Trial: 37879536
Drug: Ivonescimab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivonescimab (all doses)
Trial: 37879695
Drug: ASTX727 (demethylating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 (demethylating agent)
Trial: 37879701
Drug: Psychoeducation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducation intervention for family carers (administered in 2-hour sessions over 9 weeks)
Trial: 37880076
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy for patients with longitudinal undetectable MRD
Trial: 37880168
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of LMWH (group C)
Trial: 37880581
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral thiamine treatment for chronic fatigue
Trial: 37880682
Drug: Metabolism-related prognostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolism-related prognostic model; validated using multiple external datasets.
Trial: 37880682
Drug: Metabolism-related prognostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolism-related prognostic model.
Trial: 37880704
Drug: High albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High albumin levels (> 36 g/L)
Trial: 37880931
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy before pregnancy
Trial: 37881307
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of anti-TNF (adalimumab 160mg) followed by a second injection of adalimumab 80mg 2-3 weeks later.
Trial: 37881307
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (saline [0.9% sodium chloride]) followed by a second injection of equivalent volume of placebo 2-3 weeks later.
Trial: 37882059
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - Estradiol valerate (1 mg) + Medroxyprogesterone acetate (2.5 mg)
Trial: 37882706
Drug: 3-week nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3-week nab-paclitaxel (125 mg/m2 on days 1 and 8)
Trial: 37882706
Drug: 4-week nab-paclitaxel
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week nab-paclitaxel (125 mg/m2 on days 1, 8, and 15)
Trial: 37882974
Drug: First subsequent
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First subsequent therapy
Trial: 37883073
Drug: Biweekly cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biweekly cabazitaxel (CBZ16), 16 mg/m2 plus G-CSF and daily prednisolone
Trial: 37883073
Drug: Triweekly cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triweekly cabazitaxel (CBZ25), 25 mg/m2 plus G-CSF and daily prednisolone
Trial: 37883081
Drug: Antiangiogenic metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic metronomic therapy (daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, intravenous bevacizumab, intraventricular therapy with alternating etoposide and cytarabine)
Trial: 37883081
Drug: Antiangiogenic metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic metronomic therapy
Trial: 37883128
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) via telehealth
Trial: 37883128
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) in-office
Trial: 37883128
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT) in-home
Trial: 37883190
Drug: Low initial
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low initial myocardial 18F-dopamine-derived radioactivity (<6,000 nCi-kg/cc-mCi)
Trial: 37883329
Drug: Microtubule-targeted agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtubule-targeted agents
Trial: 37883329
Drug: Drug that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug that increases CIN
Trial: 37883413
Drug: Medicine Information
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine Information Helpline (MIH)
Trial: 37883723
Drug: Biomarker group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker group (specific targeted agents plus paclitaxel)
Trial: 37883727
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin induction therapy
Trial: 37883739
Drug: Response-Adjusted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-Adjusted Therapy
Trial: 37883738
Drug: Total Neoadjuvant
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Neoadjuvant Therapy
Trial: 37883795
Drug: CAR-T cells
RxNorm normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cells (CTL019) with time-limited ibrutinib, started before leukapheresis and continued for a minimum of 6 months post-CAR-T administration.
Trial: 37883802
Drug: rFXIII-A2 infusion
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFXIII-A2 infusion
Trial: 37883997
Drug: Cryocompression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryocompression therapy on dominant hand and foot
Trial: 37883997
Drug: Cryocompression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryocompression therapy
Trial: 37884337
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) stimulation as an adjunct therapy to lumbar spinal fusion procedures
Trial: 37884680
Drug: Digital lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital lifestyle treatment
Trial: 37884972
Drug: Short-chain fatty
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain fatty acids (SCFAs) - acetate, propionate, butyrate delivered via pH-dependent colon-delivery capsules for six weeks
Trial: 37885026
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IVI) - ferric derisomaltose
Trial: 37885233
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine Sodium Soft Gelatin Capsules
Trial: 37885445
Drug: Multi-ingredient herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-ingredient herbal supplement (12 weeks)
Trial: 37885795
Drug: Primary series
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary series (2 doses)
Trial: 37885795
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose (monovalent)
Trial: 37886040
Drug: Residential substance
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential substance use treatment
Trial: 37886114
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for 12 weeks
Trial: 37886114
Drug: Play-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Play-based therapy for 12 weeks
Trial: 37886458
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg PO plus standard treatment
Trial: 37886645
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor (SSTR)-2+ treatment
Trial: 37886872
Drug: P2B001 (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2B001 (0.6 mg pramipexole and 0.75 mg rasagiline)
Trial: 37887975
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (6 g/day)
Trial: 37888914
Drug: Inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin (20 mg/kg ideal body weight once daily for 3 days)
Trial: 37888914
Drug: Inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin
Trial: 37888917
Drug: Nemolizumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (60 mg initial dose, followed by 30 mg or 60 mg every 4 weeks for 16 weeks)
Trial: 37888916
Drug: Patisiran (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (0.3 mg/kg body weight, once every 3 weeks for 12 months)
Trial: 37889100
Drug: PICU Supports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PICU Supports intervention involving trained family navigators who assessed and addressed parent needs, offered weekly family meetings, and provided post-PICU discharge check-ins.
Trial: 37889107
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma with a neutralizing antibody titer of at least 1:320 (or 1:160 for 17.7% of patients)
Trial: 37889308
Drug: 24-week exercise
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24-week exercise intervention during BEP-chemotherapy (group A)
Trial: 37889308
Drug: 24-week exercise
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24-week exercise intervention after BEP-chemotherapy (group B)
Trial: 37889382
Drug: Pemigatinib 13.5
RxNorm normalized name: pemigatinib 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemigatinib 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule
Trial: 37889486
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel daily
Trial: 37889486
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel daily
Trial: 37889513
Drug: RTS,S/AS02A malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02A malaria vaccine
Trial: 37889522
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 685509 (2 mg BID)
Trial: 37889522
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 685509 (3 mg BID)
Trial: 37889522
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 685509 (1, 2, or 3 mg BID)
Trial: 37889541
Drug: Varenicline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline + Oral NRT (VAR+NRT)
Trial: 37889541
Drug: Smartphone medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone medication reminders (REM)
Trial: 37889541
Drug: Varenicline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline + Oral NRT (VAR+NRT) with reminders (REM)
Trial: 37889541
Drug: Overall medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall medication adherence (assessed via the Medication Adherence Questionnaire)
Trial: 37890035
Drug: Low-density lipoprotein
RxNorm normalized name: Low-density lipoprotein receptor kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-density lipoprotein (LDL) levels < 100 mg/dL
Trial: 37890351
Drug: Nivolumab (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (360 mg) plus eribulin (1.4 mg/m²)
Trial: 38805733
Drug: Low-level light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light therapy (LLLT)
Trial: 37890960
Drug: Xylitol syrup
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol syrup (two times per day for 6 months)
Trial: 37890960
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup with sorbitol (two times per day for 6 months)
Trial: 37890960
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup with sorbitol
Trial: 37890987
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) with medical care in No-IVT stratum
Trial: 37890987
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) with medical care in IVT stratum
Trial: 37890987
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) in IVT stratum
Trial: 37890987
Drug: No-Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-Endovascular therapy (No-EVT) in IVT stratum
Trial: 37890987
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) in No-IVT stratum
Trial: 37890987
Drug: No-Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-Endovascular therapy (No-EVT) in No-IVT stratum
Trial: 37891072
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of treatment (Cohort A, n=10)
Trial: 37891072
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of treatment (Cohort B, n=10)
Trial: 37891072
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events (AEs) related to treatment
Trial: 37891178
Drug: EPP-AF® (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPP-AF® (900 mg/day for 10 days)
Trial: 37891226
Drug: Zinc and
RxNorm normalized name: Zinc and/or zinc compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc and vitamin E supplementation (1200 IU vitamin E and 120 mg elemental zinc the day before surgery, followed by 30 mg zinc and 200 IU vitamin E daily from the 2nd day after surgery to 3 weeks)
Trial: 37891522
Drug: Fluoxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine combined with cognitive-behavioural therapy (CBT)
Trial: 37891522
Drug: Sertraline, vortioxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline, vortioxetine, or duloxetine (for nonresponders)
Trial: 37891522
Drug: Aripiprazole, olanzapine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole, olanzapine, or lithium carbonate added to fluoxetine (for nonresponders)
Trial: 37891549
Drug: 2% HA
RxNorm normalized name: GNP Antibacterial 2% Hand Soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% HA gel with PBMT (diode laser 980 nm, 0.2 W)
Trial: 37891566
Drug: Concerns about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerns about medication
Trial: 37891566
Drug: Beliefs about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs about overprescribing medication
Trial: 37891574
Drug: Perioperative mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative mental health (PMH) bundle including behavioral activation (BA) and medication optimization (MO)
Trial: 37891608
Drug: PACAP (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACAP (0.1 mg/ml, 6 μl, intranasally for 4 weeks)
Trial: 37891616
Drug: Oral fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fosfomycin
Trial: 37892573
Drug: Norepinephrine Zero-Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine Zero-Bolus High-Infusion (Group ZBHI, 0 µg/0.1 µg kg)
Trial: 37892573
Drug: Norepinephrine (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (other dosing schemes not specified)
Trial: 37892656
Drug: Normal life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal life with emphasis on glycemic controls before and after daily physical exercise.
Trial: 37893050
Drug: Daily change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily change of PSP
Trial: 37893050
Drug: Daily change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily change of CRP
Trial: 37893050
Drug: Daily change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily change of PCT
Trial: 37894368
Drug: Pre-operative mechanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative mechanical bowel preparation
Trial: 37894732
Drug: Sirolimus (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (0.5-2 mg/day)
Trial: 37896832
Drug: Higher HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity
Trial: 37897395
Drug: Stromal vascular
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stromal vascular fraction injection
Trial: 37897472
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of allogeneic off-the-shelf CD45RA T cells
Trial: 37897566
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment
Trial: 37897566
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro effect of metformin
Trial: 37897866
Drug: Matched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched therapy recommended by multidisciplinary tumor board (MTB)
Trial: 37897866
Drug: Treatment based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment based on genomic profiling
Trial: 37898146
Drug: Oral PrEP
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PrEP (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate)